

# DRUG METABOLISM AND DISPOSITION

A Publication of the American Society for Pharmacology and Experimental Therapeutics

March 2020

Vol. 48, No. 3

## CONTENTS

### MINIREVIEW

- Induction of Human Intestinal and Hepatic Organic Anion Transporting Polypeptides: Where Is the Evidence for Its Relevance in Drug-Drug Interactions?. *A. David Rodrigues, Yurong Lai, Hong Shen, Manthena V.S. Varma, Andrew Rowland, and Stefan Oswald* . . . . . **205**

- Carboxylesterase 1 and Precision Pharmacotherapy: Pharmacogenetics and Nongenetic Regulators. *Lucy Her, and Hao-Jie Zhu* . . . . . **230**

### ARTICLE

- Identification and Characterization of a New Carboxylesterase 2 Isozyme, mfCES2C, in the Small Intestine of Cynomolgus Monkeys. *Kayoko Ohura, Yoshiyuki Igawa, Maori Tanaka, Kana Matsumoto, Akiko Kasahara, Naoya Wada, Kazuishi Kubota, Yasuhiro Uno, and Teruko Imai* **146**

- Intracellular Cytidine Deaminase Regulates Gemcitabine Metabolism in Pancreatic Cancer Cell Lines. *Tormod K. Bjånes, Lars Petter Jordheim, Jan Schjøtt, Tina Kamceva, Emeline Cros-Perrial, Anika Langer, Gorka Ruiz de Garibay, Spiros Kotopoulos, Emmet McCormack, and Bettina Riedel* **153**

- UDP-Glycosyltransferase 3A Metabolism of Polycyclic Aromatic Hydrocarbons: Potential Importance in Aerodigestive Tract Tissues. *Ana G. Vergara, Christy J.W. Watson, Gang Chen, and Philip Lazarus* . . . . . **160**

- Influence of Uridine Diphosphate Glucuronosyltransferase Family 1 Member A1 and Solute Carrier Organic Anion Transporter Family 1 Member B1 Polymorphisms and Efavirenz on Bilirubin

- Disposition in Healthy Volunteers. *Kimberly S. Collins, Ingrid F. Metzger, Brandon T. Gufford, Jessica B. Lu, Elizabeth B. Medeiros, Victoria M. Pratt, Todd C. Skaar, and Zeruesenay Desta* . . . **169**

- Use of Phenotypically Poor Metabolizer Individual Donor Human Liver Microsomes To Identify Selective Substrates of UGT2B10. *Nicolo Milani, NaHong Qiu, Birgit Molitor, Justine Badée, Gabriele Cruciani, and Stephen Fowler* . . . . . **176**

- Carbonyl Reductase 1 Plays a Significant Role in Converting Doxorubicin to Cardiotoxic Doxorubicinol in Mouse Liver, but the Majority of the Doxorubicinol-Forming Activity Remains Unidentified. *Daniel H. Breyse, Ryan M. Boone, Cameron M. Long, Miranda E. Merrill, Christopher M. Schaupp, Collin C. White, Terrance J. Kavanagh, Edward E. Schmidt, and Gary F. Merrill* . . . . . **187**

- The Human UGT2B7 Nanodisc. *Ian Cook, Anna B. Asenjo, Hernando Sosa, and Thomas S. Leyh* . . . **198**

- Biotransformation Pathways and Metabolite Profiles of Oral [<sup>14</sup>C]Alisertib (MLN8237), an Investigational Aurora A Kinase Inhibitor, in Patients with Advanced Solid Tumors. *Sandeepraj Pusalkar, Xiaofei Zhou, Yuexian Li, Lawrence Cohen, Jun Johnny Yang, Suresh K. Balani, Cindy Xia, Wen Chyi Shyu, Chuang Lu, Karthik Venkatakrishnan, and Swapan K. Chowdhury* . . . . . **217**

### ERRATUM

- Correction to "A Role for the Orphan Human Cytochrome P450 2S1 in Polyunsaturated Fatty Acid  $\omega$ -1 Hydroxylation Using an Untargeted Metabolomic Approach". . . . . **159**

Supplemental material is available online at <http://dmd.aspetjournals.org>.

*About the cover:* The art presents a model of the Human UGT2B7 Nanodisc constructed using Homology Modelling and Molecular Dynamics. See the article by Cook et al. ([dx.doi.org/10.1124/dmd.119.089946](https://doi.org/10.1124/dmd.119.089946)).